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The human C3b/C4b receptor (CR1) is a single polypeptide chain glycopro-
tein, first isolated from the erythrocyte membrane (1), that plays an important
role in the regulation ofthe activation of the complement system. It is a cofactor
of Factor I in the cleavage ofC3b and C4b, and a potent inhibitor of the C3/C5
convertases of both the classical and the alternate pathways (1, 2). In addition,
CR1 has a major role in the processing and clearance of circulating immune
complexes (3, 4). Genetically, CR1 is encoded by C3bR, a polymorphic locus that
determines at least four alleles, C3bR-A, C3bR-B, C3bR-C and C3bR-D, the
products of which differ in their M, on SDS-PAGE (5-8).
Linkage analysis ofthe loci encoding C4-binding protein (C4BP), CR1 (C3bR),
and Factor H (FH)' in informative families demonstrated that these three genes
are closely linked in humans (9, 10). The C4BP locus is so closely linked to the
C3bR locus that no recombinants have been observed thus far, and complete
linkage disequilibrium exists between the C4BP-2 and C3bR-B alleles (9, and our
unpublishedobservations)in studies comprising 130 families and severalhundred
unrelated individuals. The distance between C4BP-C3bR and FH has been
estimated in the range of 5-10 cm (10 and our unpublished observations). We
have named this linkage group the regulator of complement activation (RCA),
and we have shown (10) that it segregates independently of HLA and ofthe C3
locus. Recently, the gene encoding CR1 has been cloned (11) and mapped to the
long arm ofchromosome 1 in humans (12), therebyestablishing the chromosomal
location of all the genes within the RCA gene cluster.
Inaddition totheelectrophoretic variation, differences have beenencountered
in the number ofCR1 molecules per red cell expressed by different individuals,
which are also believed to be under genetic control (13-15). The nature and the
mode ofinheritance of this regulatory control are unclear. It has been proposed
(15), for example, that these quantitative variations are controlled by a diallelic
locus, designated C3bRQ. Under this model, the phenotypic frequencies of the
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quantitative variants should fit a trimodal distribution in the population, a
proposition that has recently been questioned (16). Quantitative variation has
also been encountered in heterozygotes for structural gene alleles. In these
people, it is possible to measure the relative quantities of CR1 produced by each
allele. The proportion is constant for each individual but varies substantially
among different qualitatively identical heterozygotes (5, 7).
In this paper we analyze the genetic relationships ofstructural and quantitative
variations of CR 1 . Our results indicate that the putative C3bRQ locus is located
within the RCA gene cluster and closely linked to the C3bR structural locus. In
addition, we show the existence of multiple alleles at the C3bRQ locus that control
the levels of expression of the CAR structural alleles by a cis-acting mechanism.
Materials and Methods
Materials. e-aminocaproic acid (EACH), NP-40, 2-ME, PMSF, EDTA, Coomassie
Brilliant Blue R, and neuraminidase type V (from Clostridium perfringens) were from
Sigma Chemical Co., St. Louis, MO. Ampholines (pH 3.5-10, 4-6, and 6-8) from LKB
Produkter, Bromma, Sweden; N,N'-methylene-bis-acrylamide, acrylamide, N,N,N',N'-
tetramethylethylenediamide, ammonium persulfate, and SDS were obtained from Bio-
Rad Laboratories, Richmond, CA; and ultrapure urea was from Schwarz-Mann Biotech,
Cambridge, MA.
Samples. Human blood samples were obtained by venipuncture and collected in
standard ACD (acid/citrate/dextrose, formula A) anticoagulant. Test were done on fresh
specimens whenever possible. Otherwise, samples were frozen and kept in the gas phase
above liquid nitrogen until used. Additionally, samples of EDTA-anticoagulated and
clotted blood were used to allotype for C4BP and FH. EDTA-plasma and serum were
separated from each specimen within 2 h of collection and stored at -80'C until use.
Allotyping ofC4BP and FH.
￿
C4BP and FH phenotyping were performed as previously
described (17) using fresh or fresh-frozen (-80'C) EDTA-plasma or serum. Samples (90
jul) were treated with I U of neuraminidase (in 10 j.1 of 1 M phosphate buffer, pH 7.0,
containing 0.2 M EDTA, 50 mM EACA, 0.5% NaN3, and I mM PMSF) for 2 h at 37°C.
C4BP and FH were immunoprecipitated using rabbit polyclonal monospecific antisera
(vol/vol), and the immunoprecipitates were washed twice in 0.1 M acetate buffer, pH 4.0,
and 0 .1 M borate buffer, pH 8 .0, both buffers containing 1 M NaCl. The immunoprecip-
itates were then dissolved in 8 M urea containing 1 % NP-40, 10% 2-ME, and 4%
ampholines (pH 3.5-10, 6-8, 4-6 ; 1 :4:4) and analyzed by IEF under completely denatur-
ing conditions on vertical 4.5% polyacrylamide slab gels. A mixture of ampholines (pH
3 .5-10, 4-6, 6-8; 1 :4:4) were used to generate the pH gradient. Gels were run for 15 h
at room temperature at 10 mA constant current, reaching the maximum voltage of 500
V. After focusing, the gels were fixed in methanol, acetic acid, and water (40 :10 :100,
vol/vol/vol), and stained with Coomassie Brilliant Blue (0.15 g/liter of methanol, acetic
acid, and water, 70:14:100, vol/vol/vol).
Allotyping and Quantitative Determinations ofC3bR Alleles by Western Blot Analysis.
￿
Red
cells were washed six times with PBS (pH 7 .2) and the packed red cells were hemolyzed
by quick-freezing and thawing. 300,1 of hemolysate (3 X 109 cells) were then mixed with
an equal volume of PBS containing I % NP-40, the mixture was made 1 mM in PMSF
and allowed to stand for 45 min at 4°C. Insoluble materials were removed by centrifuga-
tion at 12,000 g at 4°C. Aliquots of each of the supernatants, (solubilized red cells) were
transferred to fresh tubes and incubated at room temperature for 2 h with an excess of
either an mAb against CR1 (57F) or purified rabbit IgG anti-human CRI (both reagents
were generous gifts of Dr. V. Nussenzweig, Department of Pathology, New York Univer-
sity, New York). Immune complexes were precipitated by incubating overnight at 4°C
with an excess of Sepharose-conjugated goat anti-mouse IgG or goat anti-rabbit IgG
(Dynatech Laboratories, Inc., Alexandria, VA) respectively. The beads were carefully
washed three times with 3 ml of PBS containing 1 % NP-40, resuspended in 100 ul of 0 .11276
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M Tris (pH 6.8) containing 2% SDS, 10% glycerol, and 0.01% bromophenol blue, and
boiled for 2 min. The total content of each tube was loaded on 5% SDS-polyacrylamide
gels with a 3% stacking gel, and electrophoresed using the discontinuous buffer system of
Laemmli (18). Electroblotting was performed in Tris-glycine (25 mM Tris and 192 mM
glycine) containing 20% (vol) methanol by using a Trans-Blot cell (Bio-Rad Laboratories)
for 7-9 h at 4°C and 250 mA, blotting onto nitrocellulose membranes (BA 85; Schleicher
and Schuell, Keene, NH). The blots were first blocked overnight at 4°C in 50 mM Tris,
150 mM NaCl, pH 8 (TN buffer) containing 20% FCS and 0.05% NaN3, and then
incubated in 10 ml of TN buffer containing 2% FCS, 0 .05% Tween-20, and '21I-labelled
antibodies against human CRI for 2 h at room temperature with gentle mixing. Rabbit
polyclonal antibodies and 57F mAb were used with similar results.' 'I-labelled antibodies
were prepared using Iodogen (Pierce Chemical Co., Rockford, IL) according to the
manufacturer's directions.
After incubation with '2'I-labelled antibodies, the nitrocellulose membranes were
washed three times with 100 ml of TN buffer containing 0.05% Tween-20, dried, and
exposed for autoradiography at -80'C using Kodak XAR-5 film and Cronex Lighting-
plus intensifying screens (DuPont Co., Wilmington, DE). A scanning densitometer, (Bio-
Rad Laboratories) was used for the quantitation of the intensity of the autoradiographic
bands.
Quantitative Determination of Total Erythrocytic CRI by Immunoradiometric Assays.
￿
The
number of CR 1 molecules on erythrocytes was measured by a specific immunoradiometric
assay using monoclonal and polyclonal anti-CRI antibodies. This assay is a modification
of methods previously described (13, 20) for studies on SLE. Briefly, 96-well microtiter
plates (Dynatech Laboratories, Inc.) were coated with anti-human CRI mAb (57F).
Solubilized red cells, prepared as described above for the quantitative determination by
Western blot analysis, were diluted 1 :20 or 1 :40 in PBS, adjusting the final concentration
of NP-40 to 0.1% . 50 I.1 were then added to triplicate wells and incubated overnight at
VC . C . The wells were then washed four times with PBS containing 1 % BSA and 0.1 % NP-
40, and the amount of bound CRI was quantitated by the addition of radiolabelled anti-
human CRI rabbit polyclonal antibody. Each determination includes the standard of a
titration of purified CRI for comparison, as well as extracts from known erythrocyte
preparations. The number of CR1 molecules was estimated by assuming an average Mr
200,000.
Results and Discussion
Variations in the number of CRI molecules on human erythrocytes was first
shownby Miyakawaetal. (14) using immuneadherencehemagglutination, which
involves the agglutination of erythrocytes by C3b-bearing immune complexes.
This initial observation was soon independently confirmed by other studies
involving direct binding of dimeric C3b (15), mAb against CR1 (13, 16), or
rabbit polyclonal anti-CRI (15) to human erythrocytes, and immunoradiometric
assays using C3b-coated (13) or anti-CRI-coated (20) microtiter plates and '25I-
anti-CR1 antibodies. All of these methods for the quantitation of CR1 yield
equivalent results, and in fact, direct comparison of erythrocytic CR1 levels
determined by these different methods showed excellent correlation (13, 15, 16,
20). In this study, we have performed the quantitative determinations of eryth-
rocytic CRI with similar immunoradiometric assays and the same reagents used
in these previous studies (13, 16, 20).
As reported previously for other population samples (13-16, 20), an almost
continuous 10-fold range variation existed in the total population sample we
studied (not shown). Also in agreement with previous studies (15), no association
was found between levels of CRI and individual CR1 structural alleles. SinceRODRIGUEZ DE CORDOBA AND RUBINSTEIN
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erythrocytic CRI levels have been shown (13-15) to be genetically determined,
we undertook the analysis of the segregation of quantitative and structural
variations of CRI within families.
Families were selected for this study if they had at least one parent heterozygous
for the RCA system, and if members of the pedigree exhibited significantly
different numbers of CRI molecules per cell . The five sibships that satisfied both
criteria are shown in Table I. Because of the tight linkage between the structural
loci C3BR, C4BP, and FH (the RCA cluster of genes), parents heterozygous for
at least one of these were informative for joint segregation with CRI levels. In
family BRU, the three children differed in at least one RCA haplotype, and
expressed very different amounts of CR1 . The combination of the paternal (Fa)
a with the maternal (Mo) c genes (child [Ch 3]) resulted in the highest number
of CRI molecules per cell, while the opposite combination, b, d (Ch 2) produced
the lowest. The number of CRI molecules per cell expressed by Ch 1 (a, d) was
intermediate between the other two, and similar to those in the parents. Accord-
ing to the codominant hypothesis of Wilson et al. (15), both parents should be
heterozygotes for alleles at the C3bRQ locusdetermining high and low expression .
The paternal a and maternal c RCA haplotypes segregated with the C3bRQ high
allele, while the other two (b and d) RCA-haplotypes segregated with the C3bRQ
low allele. Family BAC had two sets of RCA-identical sibling pairs that differed
in one haplotype. Overall, this family had lower numbers of CRI molecules than
family BRU ; both BAC parents were in the range of the lowest expression of
CRI in BRU, Ch 2. Each set of RCA-identical sibling pairs expressed similar
numbers of CRI that differed significantly from the other set, the lower being
significantly below those in Ch 2 in BRU . These two families, taken together,
indicate that the number of alleles at the quantitative control locus exceeds the
two suggested in the earlier literature (I5). Family PRE was similar. Again, there
are two sets of RCA-identical sibling pairs each with very much the same numbers
of CRI molecules. The broad range of these quantitative phenotypes further
indicates the existence of multiple C3bRQ alleles.
In family FRI, the mother's RCA haplotypes are structurally indistinguishable,
but the inheritance of the paternal RCA haplotypes is easily discernible. Thus,
the father's a haplotype, in Ch 4, 5, and 6 resulted in levels of CRI significantly
higher than those present on the erythrocytes of Ch 1, 2, and 3, who inherited
the paternal RCA haplotype b.
In family CYP, duplicate or triplicate examples of all four possible RCA
genotypes were observed, each set characterized by a common quantitative
phenotype.
These data, therefore, indicate that the number of CRI molecules per cell is
inherited, and that it segregates together with the RCA gene cluster. After
completion of this work, we learned of results by Wilson et al. (19), who used a
cloned cDNA probe to detect human CRI-restriction fragment length polymor-
phisms, and obtained data consistent with this conclusion. Additionally, the
quantitative control gene (C3bRQ) segregating with the RCA haplotypes must be
highly polymorphic (i.e., it must have multiple discrete alleles). Because of the
reproducibility of C3bRQ phenotypes in siblings, this gene appears to be solely
responsible for the control of CRI expression. This conclusion further suggests1278
￿
GENETIC CONTROL OF CRI EXPRESSION
TABLE I
Segregation ofRCA Haplotypes and Erythrocytic CRI Levels
* RCA typing is indicated for each paternal (a, b) or maternal (c, d) RCA haplotypes, i.e., (a) 1, B, 1
is (a) C4BP-1, C3bR-B, FH-1. Typings were performed as described in Materialsand Methods.
x CRI levels were determined by immunoradiometric assays (see Materials and Methods). Number
of CRI molecules were estimated by assuming an average M, for CRI of 200,000. Duplicate
measurements from the same blood sample agree within 5%; from different samples, assayed
independently, within 10%.
Family Members RCA typing*
CR1 levels
(molecules per
cell)#
BRU
Fa (a) I, B, 1; (b) 2, B, 1 548
Mo (c) 1, A, 1; (d) 1, A, 2 463
Chl a, d 421
Ch2 b, d 203
Ch3 a, c 741
BAC
Fa (a) 1, A, 1; (b) 3, A, 1 164
Mo (c) 1, A, 1; (d) 1, A, 2 180
Chl b, d 53
Ch2 b, d 59
Ch3 b, c 206
Ch4 b, c 296
FRI
Fa (a) 1, A, 1; (b) 1, B, 1 490
Mo (c) 1, A, 1; (d) 1, A, 1 70
Ch l b, cor d 200
Ch2 b, c or d 125
Ch3 b, cor d 120
CH a, c or d 380
Ch5 a, c or d 360
Ch6 a, c or d 300
PRE
Fa (a) 1, A, 1; (b) 1, B, 2 456
Mo (c) 1, A, 1; (d) 1, D, 1 78
Ch l a, d 250
Ch2 a, d 210
Ch3 b, c 160
Ch4 b, c 153
CYP
Fa (a) 1, B, 1; (b) 1, A, 1 270
Mo (c) 1, A, 2; (d) 1, A, 1 600
Chl b, d 695
Ch2 b, d 500
Ch3 b, c 603
Ch4 b, c 595
Ch5 b, c 419
Ch6 a, d 419
Ch7 a, d 390
CH a, d 388
Ch9 a, c 262
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FIGURE 1 .
￿
Cis-regulation of erythrocytic CR1 levels, polymorphism, and inheritance of the
C3bRQalleles with theC3bR alleles . Twoquantitative Western blots illustrating the segregation
of structural and quantitative variants of CR1 in two informative families . Total erythrocytic
levels of CR1 (molecules per erythrocyte) are indicated at the bottom for Fa, Mo,andCh .
that the same control mechanism may account for the observation that CR1
heterozygotes often express different amounts of CR1 in each of their two
electrophoretically separated allelic gene products .
Fig . 1 and Table II demonstrate these quantitative variations at the allelic
level . In each of the families in Table II there are two RCA-identical C3bR-
heterozygous sibling pairs who fail to shareRCA haplotypes with the other pair .
In each pedigree, the fraction of the total CR1 contributed by each C3bR allele
is constant in RCA-identical siblings .
These data, taken together with those in Table I, are consistent with the
suggestions that C3bRQexclusively determines the quantity ofCR1 produced by
the corresponding haplotype, and that the total number of molecules per cell is
equal to the sum of the molecules contributed by the two haplotypes under their
respective controls. To test this hypothesis, we determined the absolute level of
expression of six individual CAR alleles, inherited by at least three family
members each, using quantitative Western blot analysis . The results, summarized
in Table 111, demonstrate that, within experimental error, the number of
molecules of CR 1 for erythrocyte is in fact inherited together with the corre-
sponding structural gene, and that it is independentofthe quantitative expression
of the paired allele .
We conclude, therefore, that quantitative variations of CR1 on human eryth-
rocytes are controlled by a multiallelic locus, designated C3bRQ, closely linked
to the CR1 structural gene and involving a rigorously cis-acting mechanism . This
quantitative control system appears to play a major, if not the sole, role in the
genetic determination of the total amounts of CR1 on normal human erythro-
cytes . Fig . 1 shows theCR 1 patterns of two pedigrees that support this conclusion .
Data from these families show that the absolute levels of expression of the
individualCAR alleles remain constant, independently of those that characterize
the paired allele . The mother in family FRI is homozygous for the structural
allele C3bR-A, but could well be heterozygous at the quantitative C3bRQ locus1280
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TABLE 11
Distinct Expressivity ofC3bR Alleles in Heterozygous Individuals
* As in Table 1.
$ Percentages of CR1 in each C3bR allele were determined by scanning densitometry of Western
blots as described in Materialsand Methods.
because the C3bR-A,B heterozygous siblings in this family show two different
levels of expression of the maternally inherited CAR-A allele. The differences
in the total number of CR1 molecules among these C3bR-A,B heterozygous
children in family FRI (Table 1) are thus attributable to thedifferent expressions
of the C3bR-A allele encoded by each ofthe maternal RCA haplotypes shown in
this figure . Therefore, the RCA-linked C3bRQ locus is sufficient to account for
the variations observed in the total erythrocytic CR1-levels.
This quantitative control gene (C3bRQ) extends the complexity and increases
the polymorphism ofthe RCA system, and individuals, otherwise identical at the
C3BP, CAR, and FH loci, such as the mothers in families BAC and CYP (Table
I), may now be shown to carry different RCA haplotypes because ofthe different
expression ofthe CAR alleles. The segregation offamily FRI (Table I and Fig.
1), in which the mother's RCA haplotypes are structurally indistinguishable
Family Members RCA typing*
Percentage of total CR1$
C3bR-A C3bR-B C3bR-D
PRE
Fa (a) 1, A, 1; (b) 1, B, 2
Mo (c) 1, A, 1; (d) 1, D, 1
Chi a, d 88 12
Ch2 a, d 89 11
Ch3 b, c 31 69
Ch4 b, c 36 64
PED
Fa (a) 2, B, 1; (b) 1, A, 2
Mo (c) 1, A, 1; (d) 1, B, 1
Chi a, d 58 42
Ch2 a, d 60 40
Ch3 b, c 41 59
Ch4 b, c 37 63
PRI
Fa (a) 1, B, 1; (b) 1, A, 2
Mo (c) 1, A, 1; (d) 1, B, 1
Chi a, c 46 54
Ch2 a, c 45 55
Ch4 b, d 75 25
Ch4 b, d 71 29
FRI
Fa (a) 1, A, 1; (b) 1, B, 1
Mo (c) 1, A, 1; (d) 1, A, 1
Chi b, c or d 57 43
Ch2 b, c or d 32 68
Ch3 b, c or d 26 74TABLE III
Constant Expression ofCAR Alleles, Identical by Descent, in Family Members
RODRIGUEZ DE CORDOBA AND RUBINSTEIN
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53.5 t 11 .2
* Inheritance of each C3bR allele was unequivocally determined by the segregation of the RCA
haplotypes.
$The level of expression of each C3bR allele in erythrocytes was determined for each individual by
quantitative Westernblot analysis and scanning densitometry. The proportion of CR1 in each band
wasthen multiplied by the totalCR1 determined immunoradiometrically, as describedin Materials
and Methods, to obtain the number of molecules percell.
Mean ±SD.
(C4BP-1, CAR-A, FH-1), shows that it is in fact possible to differentiate such
haplotypes on the basis of C3bRQ.
Because of the functional relevance of CR1 to the processing of immune
complexes (3, 4), it has been proposed (13-15) that quantitative differences of
CR1 play a significant role in determining an individual's susceptibility to SLE.
Family Members RCA haplotype*
Level of expression of
C3bR allele
(Molecules per cell)*
FRI
Fa 1, B, 1 113
Chl 86
Ch2 85
Ch3 89
96 ± 14.8§
PRE
Fa 1, A, 1 296
Chl 220
CH 187
234 t 55.9
Fa 1, B, 2 159
Ch3 110
CH 98
122 ± 32.3
Mo 1, A, 1 50
Chl 50
Ch2 55
51 .7 ± 2.9
Mo 1, D, 1 27
Ch3 30
Ch4 23
26.7 ± 3.5
CYP
Fa 1, B, 1 43
Ch6 58
Ch7 66
Ch8 66
Ch9 42
Ch10 461282
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The studies reported here, showing that the quantitative genetic control of
erythrocytic CR 1 is inherited with the RCA gene cluster, provide a new way to
explore the possible association between CR 1 levels and disease. We may precisely
characterize the C3bRQ allele within the relevant RCA haplotypes in healthy
relatives of patients unencumbered by the quantitative changes induced by the
disease itself. Additionally, by following the other markers of the RCA cluster,
we could use these quantitative variants as genetic markers for the study of
genetic association and linkage, and potentially for the study of the patho-
physiologic mechanisms.
Summary
The genetic relationships of quantitative and structural variations of the
C3b/C4b receptor (CRI) in human erythrocytes have been analyzed in inform-
ative families. Our results demonstrate the existence of multiple discrete quan-
titative variations of CR 1 controlled by a locus, C3bRQ, closely linked to the CR 1
structural locus, C3bR. Since the amounts of CRI produced by each C3bR allele
are shown to be independently regulated, we propose that a cis-acting genetic
mechanism controls the level of expression of the C3bR alleles, and that this
quantitative control plays a major, if not the sole, role in determining the total
amounts of CRI on normal human erythrocytes.
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